XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Net sales $ 726,796 $ 571,644
Cost of goods sold 326,169 254,276
Gross profit 400,627 317,368
Selling, general and administrative expense 225,853 193,692
Research and Development Expense 73,912 49,303
Segment profit (loss) 100,862 74,373
Interest expense 398 5,690
Foreign exchange (gains) losses, net 71 928
Marketable Securities, Unrealized (Gain) Loss (1,179,403) (827,671)
Other Nonoperating Income (Expense) 17,407 3,273
Income before income taxes 1,297,203 898,699
(Provision) benefit for income taxes (319,789) (212,787)
Net income attributable to Bio-Rad $ 977,414 $ 685,912
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad $ 32.77 $ 22.97
Weighted average common shares - basic 29,823 29,865
Diluted earnings per share:    
Net income per share diluted attributable to Bio-Rad $ 32.38 $ 22.72
Weighted average common shares - diluted 30,186 30,196